Together these studies highlight the potential of CHK1 inhibition to treat blood cancer in humans but it remains unclear if CHK1 function is needed mainly for transformation, tumor maintenance, or both. This evidence concerns the gene CHEK1 and hematopoietic and lymphoid system neoplasm.